Bevacizumab for Neovascular Age-related Macular Degeneration
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- Registration Number
- NCT01306591
- Lead Sponsor
- Peking University People's Hospital
- Brief Summary
Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the effective therapeutic approach that the majority of patients in China can bear establishing a suitable treatment for China.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 210
- Clinical diagnosis of neovascular Age-related macular degeneration
- Signed informed consent
- No other ocular fundus diseases
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Bevacizumab 1 Bevacizumab 1 - Bevacizumab 2 Bevacizumab -
- Primary Outcome Measures
Name Time Method EDTRS visual acuity score 0week(baseline), 6week, 12week, 18week, 24week, 30week, 36week, 42week, 48week EDTRS visual acuity score is assessed at each timepoint for every group
- Secondary Outcome Measures
Name Time Method macular thickness in OCT 0week(baseline), 6week, 12week, 18week, 24week, 30week, 36week, 42week, 48week macular thickness is assessed at each timepoint for every group
Trial Locations
- Locations (1)
Xiaoxin Li
🇨🇳Beijing, Beijing, China